港股新上市公司轩竹生物-B（02575）今日盘中大跌6.54%，引发市场关注。该公司昨日刚在港交所挂牌上市，首日表现强劲，收盘大涨126.72%。
轩竹生物是一家创新驱动的生物制药公司，专注于消化系统疾病、肿瘤和非酒精性脂肪性肝炎等领域的药物研发。公司目前已有三款商业化产品，并拥有超过十种在研药物资产。尽管收入呈增长趋势，但公司仍处于亏损状态。
分析人士认为，今日股价回调主要有以下几个原因：首先，昨日强劲的上市表现可能引发了部分投资者的获利回吐；其次，市场可能正在重新评估公司估值，考虑到其尚未盈利的状况；此外，整体市场情绪或生物科技板块的波动也可能对股价产生影响。
虽然短期内股价出现波动，但轩竹生物的长期发展前景仍值得关注。公司丰富的产品管线和持续的研发投入，可能为其未来业绩增长提供支撑。投资者在关注该股时，需要同时考虑其创新能力、商业化进展以及整体行业环境等多重因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.